BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CureMark Announces New Patent Covering Treatment of Drug and Alcohol Addiction


11/28/2012 9:13:19 AM

RYE, N.Y., Nov. 27, 2012 /PRNewswire/ -- Curemark announced today that it has been granted patent #8,318,158 for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction. This is the second in a series of patent grants for this indication. The newest patent is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same."

"Individuals with drug and alcohol addiction have impairments in protein breakdown. The ability to identify those individuals and subsequently treat them is a big step forward in the management of their addictions," states Dr. Joan Fallon, founder and CEO of Curemark. "In the past, addiction has been examined in the silo of the disease with little consideration of the contributory or resultant symptoms."

Dr. Matthew Heil, Curemark's Chief Scientific Officer, adds, "The National Institute on Alcohol Abuse and Alcoholism continues to examine the effects of alcohol on the body. We believe that our findings with respect to those affected with alcohol addiction may shed light upon the etiology of this debilitating disease. Curemark's understanding of the effects of impairments in protein breakdown on the brain will lead the way into a new paradigm for treatment of multiple disease states."

In December 2011, Curemark reported that its Phase III double-blind randomized placebo-controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. The trial compared CM-AT to placebo in children with autism 3-8 years of age. Top line results demonstrate a statistically significant effect of CM-AT over placebo on both the core and non-core symptoms of autism, the company said.

The FDA has placed CM-AT into the Fast Track program which facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company announced in December, 2011, that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC



Read at BioSpace.com

CureMark
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES